Sanofi-A Ventis Deutschland Gmbh

Aventis Pharmaceuticals Inc.

Joseph T Klein

Kenneth J Bordeau

Gregory H Merriman

Brian K Whiteley

Siegfried Stengelin

Matthias Gossel

Thomas Klabunde

Martin Smrcina

Pavel Safar

Carolina Lanter

James Spoonamore

Zhaoxia Yang

Nicholas J Hrib

John G Jurcak

Michael R Angelastro

Stefanie Flohr

Philip M Weintraub

Petra Lennig

Alexandre Gross

Ramalinga M Dharanipragada

Kwon Yon Musick

Gregory Shutske

Jeffrey Stephen Sabol

Petra Stahl

Keith John Harris

Stanly John

Jinqi Lu

Catherine Bomont

Keith J Harris

The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.

Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids

The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R, R, R, R, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.

3-piperidinylisochroman-5-ols as dopamine agonists

Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments

This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

Indole derivatives as interleukin-4 gene expression inhibitors

Growing community of inventors

Neshanic Station, NJ, United States of America

Joseph T Klein